Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) is a new CFTR (Cystic Fibrosis
Transmembrane Conductance Regulator) modulator treatment, used over the last few years …

Highly-effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator
therapy (HEMT) corrects the underlying molecular defect causing cystic fibrosis (CF) …

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR), which lead to early death due to progressive lung disease. The …

Background The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator,
ivacaftor, was first approved for people with CF and the G551D CFTR mutation. This study …

Background Cystic fibrosis (CF) is a multisystem disease that often requires otolaryngology
care. Individuals with CF commonly have chronic rhinosinusitis but also present with hearing …

Abstract Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious
in people with cystic fibrosis (CF) heterozygous for F508del and a minimal function mutation …

Background: Modulator therapy represents a significant step forward in CF care and is
expected to have a significant impact on the health and mortality of many individuals with …

Objectives The 22‐question SinoNasal Outcome Test (SNOT‐22) assesses chronic
rhinosinusitis (CRS) severity. We aimed to identify predictors of SNOT‐22 score …

Background Cystic fibrosis (CF) chronic rhinosinusitis (CRS) has emerged as a distinct
diagnostic entity, unique from other endotypes of CRS in its presentation, pathophysiology …

Background: The introduction of CFTR modulators has changed the landscape in the
treatment of cystic fibrosis (CF) and early case series have shown improvements in …